| Literature DB >> 28629124 |
Carla Zannella1, Francesco Mosca2, Francesca Mariani3, Gianluigi Franci4, Veronica Folliero5, Marilena Galdiero6, Pietro Giorgio Tiscar7, Massimiliano Galdiero8.
Abstract
A variety of bivalve mollusks (phylum Mollusca, class Bivalvia) constitute a prominent commodity in fisheries and aquacultures, but are also crucial in order to preserve our ecosystem's complexity and function. Bivalve mollusks, such as clams, mussels, oysters and scallops, are relevant bred species, and their global farming maintains a high incremental annual growth rate, representing a considerable proportion of the overall fishery activities. Bivalve mollusks are filter feeders; therefore by filtering a great quantity of water, they may bioaccumulate in their tissues a high number of microorganisms that can be considered infectious for humans and higher vertebrates. Moreover, since some pathogens are also able to infect bivalve mollusks, they are a threat for the entire mollusk farming industry. In consideration of the leading role in aquaculture and the growing financial importance of bivalve farming, much interest has been recently devoted to investigate the pathogenesis of infectious diseases of these mollusks in order to be prepared for public health emergencies and to avoid dreadful income losses. Several bacterial and viral pathogens will be described herein. Despite the minor complexity of the organization of the immune system of bivalves, compared to mammalian immune systems, a precise description of the different mechanisms that induce its activation and functioning is still missing. In the present review, a substantial consideration will be devoted in outlining the immune responses of bivalves and their repertoire of immune cells. Finally, we will focus on the description of antimicrobial peptides that have been identified and characterized in bivalve mollusks. Their structural and antimicrobial features are also of great interest for the biotechnology sector as antimicrobial templates to combat the increasing antibiotic-resistance of different pathogenic bacteria that plague the human population all over the world.Entities:
Keywords: antimicrobial peptides; bivalve immune system; marine bivalve mollusks
Mesh:
Substances:
Year: 2017 PMID: 28629124 PMCID: PMC5484132 DOI: 10.3390/md15060182
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Main viral infectious diseases of marine bivalve mollusks.
| Disease | Host Species | Effects on Host | Geographical Distribution | References |
|---|---|---|---|---|
| Herpes virus infection | Mainly hatchery-reared larvae of | Velar and mantle lesions; deterioration; swim in circles | Europe (France, Ireland, Italy, The Netherlands, Spain); U.K.; Australia; New Zealand, Mexico, USA, Japan, South Korea, China | [ |
| Gill necrosis virus (GNV) | Destruction of gill filaments | France, Portugal, Spain, U.K. | [ | |
| Hemocyte infection virus (HIV) | Virus infected hemocytes | France, Spain | ||
| Oyster velar virus disease (OVV) | Larval movement affected through loss of infected epithelial cells from velum | Washington State, USA | ||
Main bacterial infectious diseases of marine bivalve mollusks.
| Disease | Host Species | Effects on Host | Geographical Distribution | References |
|---|---|---|---|---|
| Larval and juvenile vibriosis | Wide range of hatchery-reared species | Tissue necrosis (due to production of exotoxin by the bacteria), up to 100% larval mortality | In all marine waters where bivalve hatchery culture is practiced | [ |
| Brown ring disease | Brown deposit on shell; degeneration of digestive gland followed by metabolic disorder and death | Entire European Atlantic coast to North Africa, including coasts of France, Portugal, Spain, Italy, U.K., Ireland and Norway, west coast of Korea | [ | |
| Roseovarius oyster disease | Reduced growth rates, fragile shell development, cupping on the left valve, mantle lesions, up to 90% mortalities | USA | [ | |
| Pacific oyster nocardiosis | Yellow-green pustules in the mantle, gills, adductor and cardiac muscle, up to 35% mortalities | West coast of North America from the Strait of Georgia, British Columbia to California, and Japan (Matsushima Bay), Mediterranean Sea | [ | |
Main protozoan infectious diseases of marine bivalve mollusks.
| Disease | Host Species | Effects on Host | Geographical Distribution | References |
|---|---|---|---|---|
| Bonamiasis | Wide range of oyster species | Yellow discoloration of tissue, extensive lesions on gill and mantle, breakdown of connective tissue, significant mortality (up to 90%) | Europe, U.K., west coast Canada, east and west coasts of USA, New Zealand and SE Australia | [ |
| Digestive gland (or Aber) disease | Pale digestive gland, severe emaciation, tissue necrosis, cessation of growth, mortalities up to 90% in summer | In | [ | |
| QX disease | Necrosis of digestive gland, loss of condition, gonad absorption, mortalities up to 90% in summer | New South Wales, Queensland and Western Australia. | [ | |
| Dermo disease | Severe emaciation, loss of condition, high mortality rate depending on temperature and salinity | Gulf of Mexico, southeast coast of USA, Pacific coast of Mexico, Gulf of California, Brazil | [ | |
Figure 1The figure reports the main phases of the hemocyte phagocytosis, as well as previously investigated in mussel (author’s unpublished figures) that are particularly described in the present section, in combination with the main humoral opsonizing and degradative factors.
Figure 2Mechanisms of interaction of AMPs with membranes. Top: The main proposed modes of action are: carpet model (1), barrel stave model (2) and toroidal-pore model (3). Bottom: Interactions of AMPs with Gram-negative and Gram-positive bacteria.
Figure 3Examples of three-dimensional structures of bivalve AMPs. * The predicted structures were designed using AIDA (ab initio domain assembly) server, a tool for the prediction of protein tridimensional structures (http://ffas.burnham.org/AIDA).
AMPs isolated from marine bivalves and main characteristics.
| Name | Source | Sequence | Length | Net Charge | % Hydrophobic Residues | Structure | Antimicrobial Activity | Reference |
|---|---|---|---|---|---|---|---|---|
| Defensin MGD-1 | GFGCPNNYQCHRHCKSIPGRCGGYCGGWHRLPCTCYRCG | 39 | 5 | 30 | Combined helix and β-sheet | Gram+ | [ | |
| Defensin MGD-2 | GFGCPNNYACHQHCKSIRGYCGGYCAGWFRLRCTCYRCG | 39 | 5 | 38 | * Combined helix and β-sheet | Gram+ and Gram− | [ | |
| Mytilin A | GCASRCKAKCAGRRCKGWASASFRGRCYCKCFRC | 34 | 10 | 47 | * Combined helix and β-sheet | Gram+ and Gram− | [ | |
| Mytilin B | SCASRCKGHCRARRCGYYVSVLYRGRCYCKCLRC | 34 | 9 | 41 | Combined helix and β-sheet | Gram+ and Gram−, antiviral | [ | |
| Myticin A | HSHACTSYWCGKFCGTASCTHYLCRVLHPGKMCACVHCSR | 40 | 4 | 45 | * Combined helix and β-sheet | Gram+ and Gram−; antifungal | [ | |
| Myticin B | HPHVCTSYYCSKFCGTAGCTRYGCRNLHRGKLCFCLHCSR | 40 | 6 | 37 | * Combined helix and β-sheet | Gram+ and Gram−; antifungal | [ | |
| Myticin C | QSVACTSYYCSKFCGSAGCSLYGCYLLHPGKICYCLHCSR | 40 | 3 | 35 | * Combined helix and β-sheet | Gram+ and Gram−; antifungal | [ | |
| Mytimycin | MSLVLRMTLLFVVCCVVIGMSNAACCHKPFWKHCWDCTAGTPYCGYRSCNIFGCGCTCRTEPYGKSCYERGNRCRCYTDKRKRRSLSFEDISPNIKFAGLDINSDGLIEQFEFIKALEQMDIIDNTTMFHHWSIMDEDKDGTITLEEFDK | 150 | −2 | 41 | * Combined helix and β-sheet | Antifungal | [ | |
| Mytimacin | MGYIGLCGVLLSLSLLMLLQIPTSDANVLGDCWEDWSRCTRQTNWFTNIAWQSCPNRCKCQGHAGGNCIQVRSNCFLWRNKRWMCNCYGRRSGPKPGWCGF | 101 | 7 | 43 | * Combined helix and β-sheet | Gram+ and Gram− | [ | |
| Big-Defensin | MNRKAILCVLYATLLIIPAPILGRVVAKKKEEKRYAAVYP IAAYAGMTVSLPVFLALVAAYGAWTVARYHIRSRSRSSSHNSHNCANNRGWCRPNCFRREYHDWYHSDTCGSYKCCRYR | 119 | 14 | 42 | * Combined helix and β-sheet | Gram+ and Gram− | [ | |
| Myticusin-1 | TDHQMAQSACIGVSQDNAYASAIPRDCHGGKTCEGICADATATMDRYSDTGGPLSIARCVNAFHFYKRRGEENVSYKPFVVSWKYGVAGCFYTHCGPNFCCCIS | 104 | 0 | 39 | * Combined helix and β-sheet | Gram+ and Gram−, antifungal | [ | |
| VpBD | LCLDQKPEMEPFRKDAQQALEPSRQRRWLHRRCLSGRGFCRAICSIFEEPVRGNIDCYFGYNCCRRMFSHYRTS | 74 | 5 | 36 | * Helix | Gram+ and Gram− | [ | |
| MCdef | GFGCPNDYSCSNHCRDSIGCRGGYCKYQLICTCYGCKKRRSIQE | 44 | 4 | 29 | * Combined helix and β-sheet | Gram+ and Gram− | [ | |
| VpDef | GFGCPEDEYECHNHCKNSVGCRGGYCDAGTLRQRCTCYGCNQKGRSIQE | 49 | 0 | 26 | * Combined helix and β-sheet | Gram+ and Gram− | [ | |
| Sb-BDef1 | MTHKIVLCCIYLLLSTSFILSKHLPEERKQKKQVLLAAGA GVALSELLGPVLVGAGTLAGAALLNQAVSSNRWVIPCANNRGWCRTDCHFGEHIDDYHSD ICHSGYKCCRY | 111 | 3 | 45 | * Combined helix and β-sheet | Gram− | [ | |
| Ap | TYMPVEEGEYIVNISYADQPKKNSPFTAKKQPGPKVDLSGVKAYGPG | 47 | 1 | 25 | * Polyproline rich β-sheet | Gram+, antifungal | [ | |
| AiBD | MTRPSLVRCYSLFFTALIVMAIICPAWSEEIPKSRKKRAIPIAYVGMAVAPQVFRWLVRAYGAAAVTAAGVTLRRVINRSRSNDNHSCYGNRGWCRSSCRSYEREYRGGNLGVCGSYKCCVT | 122 | 14 | 44 | * Combined helix and β-sheet | Gram+ and Gram−, antifungal | [ | |
| AOD | GFGCPWNRYQCHSHCRSIGRLGGYCAGSLRLTCTCYRS | 38 | 5 | 34 | * Combined helix and β-sheet | Gram+ and Gram− | [ | |
| Cg-Prp | ILENLLARSTNEDREGSIFDTGPIRRPKPRPRPRPEG | 37 | 2 | 21 | * Proline-rich peptide | Synergistic antimicrobial activity with Cg-Def | [ | |
| cgMolluscidin | AATAKKGAKKADAPAKPKKATKPKSPKKAAKKAGAKKGVKRAGKKGAKKTTKAKK | 55 | 23 | 29 | * Helix | Gram+ and Gram− | [ | |
| Cg-Defh1 | GFGCPRDQYKCNSHCQSIGCRAGYCDAVTLWLRCTCTDCNGKK | 43 | 3 | 37 | Combined helix and β-sheet | Gram+ and Gram− | [ | |
| Cg-Defh2 | GFGCPGDQYECNRHCRSIGCRAGYCDAVTLWLRCTCTGCSGKK | 43 | 3 | 37 | * Combined helix and β-sheet | Gram+ and Gram− | [ |
* The predicted structures were designed using AIDA (http://ffas.burnham.org/AIDA).